Cargando…

DIPG-24. BRD4 INHIBITION AS A RADIOSENSITIZER THROUGH BLOCKING DNA REPAIR FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA

Diffuse intrinsic pontine glioma (DIPG) is one of the devastating childhood cancers. Radiation therapy (RT) remains the only effective treatment yet provides a 5-year survival rate of only 1%. Several clinical trials have attempted to enhance RT efficacy by combining it with radiosensitizing agents,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Jun, Clutter, Matt, Hoeman, Christine, Amreena, Sui, Abe, Koki, Ishi, Yukitomo, Uchida, Eita, Becker, Oren, Hashizume, Rintaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Diffuse Intrinsic Pontine Glioma/Diffuse Midline Gliomas - DPIG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259950/ http://dx.doi.org/10.1093/neuonc/noad073.071

Ejemplares similares

DIPG-18. AI HUNTING FOR NEW DRUGS IN PEDIATRIC GLIOMA
por: Hashizume, Rintaro, et al.
Publicado: (2023)

DIPG-44. DIFFUSE MIDLINE GLIOMA WITH EXTRACRANIAL METASTASIS
por: Larsen, Alexandra Giantini, et al.
Publicado: (2023)

DIPG-05. EVALUATION OF TELOMERE-MODIFYING COMPOUND THIO AS A RADIOSENSITIZER AND IMMUNOMODULATOR TO TREAT DIPG
por: Mishra, Deepak, et al.
Publicado: (2023)

DIPG-01. LIN28B EXPRESSION IN DIFFUSE MIDLINE GLIOMA
por: Knowles, Truman, et al.
Publicado: (2023)

DIPG-22. TRIPTOLIDE AS A POTENTIALLY PROMISING THERAPY FOR DIFFUSE MIDLINE GLIOMA
por: Ciani, Ludovica, et al.
Publicado: (2023)

DIPG-20. DELINEATING MEDIATORS OF ONCOGENESIS IN FOXR2-EXPRESSING DIFFUSE MIDLINE GLIOMAS
por: Tsai, Jessica, et al.
Publicado: (2023)

DIPG-09. ATOVAQUONE RADIOSENSITISES DIFFUSE MIDLINE GLIOMAS BY INHIBITING MITOCHONDRIAL METABOLISM AND HYPOXIA
por: Mudassar, Faiqa, et al.
Publicado: (2023)

DIPG-28. IDENTIFICATION AND TARGETING OF METABOLIC VULNERABILITIES IN COMBINATION WITH PDGFRA-INHIBITION IN DIFFUSE MIDLINE GLIOMA
por: Neyazi, Sina, et al.
Publicado: (2023)

DIPG-46. TARGETING THE METABOLIC ERK5-PFKFB3 AXIS IN PEDIATRIC DIFFUSE MIDLINE GLIOMA
por: Casillo, Stephanie, et al.
Publicado: (2023)

DIPG-21. LINKING DETERMINATION OF CELL FATE IN THE DEVELOPING CENTRAL NERVOUS SYSTEM TO DIFFUSE MIDLINE GLIOMA
por: Furst, Liam, et al.
Publicado: (2023)

DIPG-11. DISSECTING THE DIFFUSE MIDLINE GLIOMA TUMOR MICROENVIRONMENT COMMUNICATIONS USING MULTI-OMICS APPROACHES
por: Collot, Raphael, et al.
Publicado: (2023)

DIPG-02. A NOVEL STRATEGY TO RADIOSENSITISE DIFFUSE MIDLINE GLIOMAS VIA DUAL-TARGETING OF GLUCOSE METABOLISM
por: Shen, Han, et al.
Publicado: (2023)

DIPG-48. DIPG THROUGH THE LOOKING GLASS
por: Senga, Sasi S
Publicado: (2023)

DIPG-51. ABDOMINAL METASTASES OF DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED WITH A VENTRICULOPERITONEAL SHUNT
por: Lazow, Margot, et al.
Publicado: (2023)

DIPG-45. ELONGIN B REGULATES H3K27M CHROMATIN INCORPORATION TO PROMOTE MALIGNANCY IN DIFFUSE MIDLINE GLIOMA
por: Anastas, Jamie, et al.
Publicado: (2023)

DIPG-49. A SYSTEMS BIOLOGY APPROACH TO DEFINING AND TARGETING CELL STATE-SPECIFIC MASTER REGULATOR DEPENDENCIES IN DIFFUSE MIDLINE GLIOMA
por: Fernández, Ester Calvo, et al.
Publicado: (2023)

DIPG-57. TESTING FOR SYNERGY AMONG RADIATION AND HIGHLY CLINICALLY RELEVANT CHEMOTHERAPEUTIC AGENTS IN PATIENT-DERIVED MODELS OF DIFFUSE MIDLINE GLIOMA
por: Slade, Mathew, et al.
Publicado: (2023)

DIPG-53. LSD1 DEGRADATION SYNERGIZES WITH HDAC INHIBITION IN PEDIATRIC H3K27M DIFFUSE MIDLINE GLIOMA
por: Haase, Rebecca, et al.
Publicado: (2023)

DIPG-32. PRECLINICAL TESTING OF THE EFFICACY AND SAFETY OF CRISPR/CAS9 GENE EDITED CAR-T CELL THERAPY FOR DIFFUSE MIDLINE GLIOMA (DMG)
por: Balakrishnan, Ilango, et al.
Publicado: (2023)

DIPG-38. PATIENT-DERIVED THREE-DIMENSIONAL AVATARS REVEAL CELL-AUTONOMOUS MECHANISMS DRIVING INVASION AND METASTATIC PROGRESSION IN DIFFUSE MIDLINE GLIOMAS
por: Bruschi, Marco, et al.
Publicado: (2023)

DIPG-16. ACUTE VERSUS PROLONGED CONVECTION-ENHANCED DELIVERY OF ALISERTIB INTO H3 K27M-MUTANT MODELS OF DIFFUSE MIDLINE GLIOMA
por: Rechberger, Julian S, et al.
Publicado: (2023)

DIPG-40. HYPOXIC STRESS EXPOSES EPIGENETIC TARGETS TO ENHANCE RADIOTHERAPY RESPONSE IN H3K27M-POSITIVE PEDIATRIC DIFFUSE MIDLINE GLIOMAS
por: de Freitas, Amanda Pereira, et al.
Publicado: (2023)

DIPG-08. THE LANDSCAPE OF TUMOR CELL STATES AND SPATIAL ORGANIZATION IN H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA ACROSS AGE AND LOCATION
por: Liu, Ilon, et al.
Publicado: (2023)

DIPG-27. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) CHALLENGE: FROM GENE EXPRESSION PROFILE TO DRUG
por: Scilimati, Antonio, et al.
Publicado: (2023)

DIPG-37. TRANSCRIPTIONAL, EPIGENETIC, AND IMMUNOLOGICAL FEATURES OF PAEDIATRIC-TYPE H3 K27-ALTERED DIFFUSE MIDLINE GLIOMAS ORIGINATING FROM DIFFERENT BRAIN LOCATIONS
por: Grabovska, Yura, et al.
Publicado: (2023)

DIPG-42. MAPPING THE DNA METHYLATION LANDSCAPE OF DIPG REVEALS NOTABLE METHYLOME VARIABILITY RESPONSIVE TO PHARMACOLOGIC MODULATION
por: Tetens, Ashley, et al.
Publicado: (2023)

DIPG-14. PROTEOGENOMICS PROFILING REVEALS ENRICHED NON-HISTONE PROTEIN METHYLTRANSFERASES AS NEW THERAPEUTIC TARGETS IN DIPG
por: Anguraj Vadivel, Arun Kumaran, et al.
Publicado: (2023)

DIPG-34. IMMUNE SYNAPSE OPTIMIZED GRP78-SPECIFIC CAR T CELLS ELICIT AN IMPROVED ANTITUMOR RESPONSE AGAINST DIPGS
por: Ibanez, Jorge, et al.
Publicado: (2023)

DIPG-52. EXTRAPONTINE PROGRESSION WITH STABLE PONTINE DISEASE POST-RADIOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ON A CONNECT TRIAL: IMPLICATIONS FOR RADIATION TREATMENT VOLUMES
por: Lazow, Margot, et al.
Publicado: (2023)

DIPG-50. INSIGHTS INTO TUMORIGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMA-ONCOHISTONE AND SIGNALING
por: Sun, Ye, et al.
Publicado: (2023)

DIPG-39. SIGNALING NETWORKS IN PEDIATRIC-TYPE DIFFUSE HIGH GRADE GLIOMAS
por: Herbst, Sophie A, et al.
Publicado: (2023)

DIPG-25. MAPPING TUMOR MICROENVIRONMENT USING EMERGING TECHNOLOGIES FOR PEDIATRIC BRAIN CANCERS
por: Laternser, Sandra, et al.
Publicado: (2023)

DIPG-10. DELTA-24-RGDOX PROMOTES ANTITUMOR IMMUNE RESPONSE IN DMG MODELS
por: Laspidea, Virginia, et al.
Publicado: (2023)

DIPG-35. IDENTIFYING DRIVER-SPECIFIC VULNERABILITIES IN PAEDIATRIC HIGH GRADE GLIOMA SUBTYPES
por: De Cola, Antonella, et al.
Publicado: (2023)

DIPG-55. DIRECT BRAIN-TO-BRAIN WORKFLOW ENABLES THE PRECLINICAL MODELING OF PEDIATRIC GLIOMAS
por: Tum, Hong, et al.
Publicado: (2023)

DIPG-23. THE ROLE OF FOXO3 IN DMG RESISTANCE AND RESPONSE TO THERAPIES TARGETING DMG METABOLISM
por: Petrovic, Antonela, et al.
Publicado: (2023)

DIPG-04. TUMOR CELL-INTRINSIC TIM-3 PROMOTES DIFFUSE INTRINSIC PONTINE GLIOMA TUMORIGENESIS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2023)

DIPG-12. OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
por: Reel, Sarah, et al.
Publicado: (2023)

DIPG-06. PRECLINICAL EVALUATION OF A NOVEL ACVR1 INHIBITOR IN DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Kumar, Shiva Senthil, et al.
Publicado: (2023)

DIPG-03. IDENTIFICATION OF NEW THERAPEUTIC TARGETS BY ARRAYED CRISPRA-BASED APPROACH TO MAP RADIORESISTANCE IN DMG
por: Fernandez, Solène, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f794fo5go7t16hoq2n87o3lutn